1 - 3 of 3
Number of results to display per page
Search Results
2. Dysfunkce endotelu a pleiotropní účinek statinů
- Creator:
- Tošovský, Marian and Bláha, Vladimír
- Type:
- model:article, article, Text, přehledy, and TEXT
- Subject:
- stárnutí--fyziologie--patologie--účinky léků, endotel cévní--patofyziologie--patologie--účinky léků, arterioskleróza--prevence a kontrola, statiny--terapeutické užití, lidé, and staří
- Language:
- Czech and English
- Description:
- Terapie statiny pozitivně působí na stabilizaci aterosklerotických plátů, restauruje funkce endotelu, má protizánětlivý efekt a signifikantně snižuje riziko akutních koronárních syndromů včetně gerontologické populace. Po disrupci plátu může snížení hladiny lipidů v séru pomocí statinů ovlivnit následující trombózu svým inhibičním divem na agregaci destiček, ovlivněním koagulačních faktorů a exprese tkáňového faktoru, vzniku trombinu a ovlivněním reologických vlastnosti a fibrinolytického systému. Vzhledem k endoteliální dysfunkci během stárnúti per se a k příznivému vlivu inhibitorů HMG-CoA reduktázy (statinů) na funkci buněk endotelu a stabilitu aterosklerotických plátů lze považovat využiti těchto farmak v léčbě endotelově dysfunkce gerontologické populace jak za klinicky relevantní, tak přínosné i nadějné., The treatment by statins positively effects stabilisation of atherosclerotic plaque, restores endothelial function, has anti-inflammatory effect and significantly improves the risk of acute coronary syndrome including the elderly. Lipid lowering by statins after plaque rupture may influence the following thrombosis via inhibitory effect on platelet aggregation, coagulation factors and tissue factor expression, thrombin formation, and may improve blood rheology and fibrinolysis. Regarding age-related endothelial dysfunction per se, and the positive effects of HMG-CoA reductase inhibitors (statins) on endothelial cell function, treatment with these drugs may be useful in age-related endothelial dysfunction., Marian Tošovský, Vladimír Bláha, and Lit. 27
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
3. The VEGF and BMP-2 Levels in Patients with Ankylosing Spondylitis and the Relationship to Treatment with Tumour Necrosis Factor Alpha Inhibitors
- Creator:
- Tošovský, Marian, Bradna, Petr, Andrýs, Ctirad, Andrýsová, Kateřina, Čermáková, Eva, and Soukup, Tomáš
- Format:
- print, text, and regular print
- Type:
- model:article, article, Text, časopisecké články, and TEXT
- Subject:
- dospělí, kostní morfogenetický protein 2--krev, C-reaktivní protein--metabolismus, progrese nemoci, ELISA, ženské pohlaví, lidé, mužské pohlaví, lidé středního věku, ankylózující spondylitida--krev--farmakoterapie, výsledek terapie, TNF-alfa--antagonisté a inhibitory, and vaskulární endoteliální růstový faktor A--krev
- Language:
- English
- Description:
- Introduction: Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterized by the development of osteoproductive changes in the spine which could possibly result in ankylosis. Treatment with tumour necrosis factor alpha (TNFα) inhibitors has proved to be an important step forward in the treatment of this disease, but for the time being it is not clear whether it favourably influences radiographic progression of the disease. Vascular endothelial growth factor most probably plays a role in the development of osteoproductive changes and recently its predictive influence on radiographic progression has been demonstrated. Bone morphogenic protein 2 (BMP-2) participates in the regulation of bone proliferation and its increased serum level has been demonstrated in patients with advanced AS and correlated with the degree of radiographic changes. Aim: The study aims to evaluate the VEGF and BMP-2 levels in patients with ankylosing spondylitis and how these levels relate to the concurrent treatment with TNFα inhibitors. Methods: Sera were evaluated from patients at the Rheumatologic Clinic of the Hradec Králové Faculty Hospital who fulfilled the modified New York Criteria for AS (n = 55). In these patients, the parameters of the activity of the disease (BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, CRP = C-reactive protein) and the concurrent therapy (TNFα inhibitors, n = 21, vs. non-anti TNFα, n = 34) were recorded. The levels of VEGF and BMP-2 were analyzed using the ELISA method. Results: In patients treated with TNFα inhibitors, a significantly lower VEGF level was found when compared to untreated patients (140.3 (109.4; 262.2) vs. 261 (172.4; 396.6) pg/ml; p = 0.02). No difference was found between BMP-2 levels in both groups (treated vs. untreated patients) (254.8 (2301; 267.3) vs. 261.1 (248.6; 273.5) pg/ml; p = 0.24). A correlation analysis did not reveal any relationship between VEG F and BMP-2 (r = 0.057; p = 0.68). Serum levels of VEGF correlated with serum levels of CRP (r = 0.56; p = 0.00001) and the BASDAI value (r = 0.33; p = 0.015). Conclusion: Significantly lower VEGF levels were found in patients treated with TNFα inhibitors versus the untreated patients. These findings are in harmony with some hitherto published analyses and may give evidence of a favourable effect of TNFα inhibitors on radiographic progression. Neither influence on the BMP-2 level by treatment with TNFα inhibitors nor correlation with VEGF levels was demonstrated. and M. Tošovský, P. Bradna, C. Andrýs, K. Andrýsová, E. Čermáková, T. Soukup
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public